Trials / Completed
CompletedNCT00728390
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
Phase 1 Targeted Combination Trial Of PF-00299804 And CP-751,871 In Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor. Each of these drugs have been given separately to patients in prior studies, and this study is to establish the safety and efficacy of the combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-00299804 | CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily. |
Timeline
- Start date
- 2008-12-15
- Primary completion
- 2011-08-09
- Completion
- 2013-01-29
- First posted
- 2008-08-05
- Last updated
- 2024-04-22
Locations
5 sites across 3 countries: United States, France, Spain
Source: ClinicalTrials.gov record NCT00728390. Inclusion in this directory is not an endorsement.